L-MYC expression maintains self-renewal and prolongs multipotency of primary human neural stem cells by Rong, Xianfang et al.




L-MYC expression maintains self-renewal and
prolongs multipotency of primary human neural
stem cells
Xianfang Rong
Washington University School of Medicine in St. Louis
Joseph Benetatos
Washington University School of Medicine in St. Louis
David L. Brody
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Rong, Xianfang; Benetatos, Joseph; Brody, David L.; and et al, ,"L-MYC expression maintains self-renewal and prolongs multipotency




L-MYC Expression Maintains Self-Renewal and Prolongs Multipotency
of Primary Human Neural Stem Cells
Zhongqi Li,1 Diana Oganesyan,1 Rachael Mooney,1 Xianfang Rong,5 Matthew J. Christensen,1
David Shahmanyan,1 Patrick M. Perrigue,3 Joseph Benetatos,5 Lusine Tsaturyan,1 Soraya Aramburo,1
Alexander J. Annala,1 Yang Lu,2 Joseph Najbauer,4 Xiwei Wu,2 Michael E. Barish,1 David L. Brody,5
Karen S. Aboody,1 and Margarita Gutova1,*
1Department of Developmental and Stem Cell Biology, City of Hope National Medical Center and Beckman Research Institute of City of Hope,
1500 East Duarte Road, Duarte, CA 91010, USA
2Integrative Genomics Core, City of Hope National Medical Center and Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
3Department of Epigenetics, Institute of Bioorganic Chemistry of the Polish Academy of Sciences, 61-704 Poznan, Poland
4Department of Immunology and Biotechnology, University of Pe´cs Medical School, Pe´cs 7624, Hungary




Pre-clinical studies indicate that neural stem cells (NSCs) can limit or reverse CNS damage through direct cell replacement, promotion
of regeneration, or delivery of therapeutic agents. Immortalized NSC lines are in growing demand due to the inherent limitations of
adult patient-derived NSCs, including availability, expandability, potential for genetic modifications, and costs. Here, we describe the
generation and characterization of a new human fetal NSC line, immortalized by transduction with L-MYC (LM-NSC008) that in vitro
displays both self-renewal and multipotent differentiation into neurons, oligodendrocytes, and astrocytes. These LM-NSC008 cells
were non-tumorigenic in vivo, andmigrated to orthotopic glioma xenografts in immunodeficientmice.When administered intranasally,
LM-NSC008 distributed specifically to sites of traumatic brain injury (TBI). These data support the therapeutic development of immor-
talized LM-NSC008 cells for allogeneic use in TBI and other CNS diseases.
INTRODUCTION
Despite decades of research, treatments for patients with
diseased or damaged regions of the CNS remain pallia-
tive at best (Pathan et al., 2009). Cell-based therapies are
emerging as a novel and potentially powerful approach
for the treatment of CNS pathologies, and multipotent
neural stem cells (NSCs) in particular are an attractive cell
type for use in CNS therapies. Recent pre-clinical proof-
of-concept studies have demonstrated the potential of
NSC-based treatments for disorders requiring neural cell
replacement (Begum et al., 2015), protection from external
insult (Umeda et al., 2016), antibody production (Kanojia
et al., 2015), and targeted delivery of therapeutic agents
(Aboody et al., 2013), including prodrug-activating en-
zymes (Metz et al., 2013). Despite these early promising re-
sults, there are still major practical limitations that must be
addressed before widespread clinical use of NSC-based ther-
apeutics is possible (Daniela et al., 2007). One constraint is
the limited number of NSCs showing consistent in vivo
behaviors and available in numbers sufficient for genetic
modification prior to administration to patients.
Practical considerations limit the use of autologous
NSCs for cell-based therapy. Allogeneic donor cells remain
an attractive possibility if an appropriate source can be
identified. Although the self-renewing NSCs present in
developing brain tissue could be used as a renewable cell
population, culture conditions have yet to be identified
that reproducibly permit continuous propagation of pri-
mary NSCs. One common approach is to expand NSC
pools by repeated subculture of polyclonal neurospheres.
However, progressive passages lead to decreased capacity
for cellular self-renewal, decreased differentiation poten-
tial, and increased accumulation of chromosomal and
functional instabilities (Reynolds and Weiss, 1992; Kallos
and Behie, 1999; Nakagawa et al., 2008). Thus a new source
of primary tissue must be obtained for each production
cycle, which makes process scale-up, regulatory approval,
and clinical translation substantially more difficult and
costly. A more practical approach has been to generate
stable, immortal NSC lines by retroviral transduction
of an MYC gene into early gestational NSC pools (Kim
et al., 2008). These MYC-immortalized NSC lines retain
their self-renewal capabilities for substantial numbers of
passages (>30 as opposed to five to six passages for non-
immortalized NSCs), which exponentially increases the
number of NSCs available for use in potential therapies
(Kim, 2004).
There have been safety-related concerns, as yet un-
realized, related to MYC-based NSC immortalization,
including the risk that an MYC transgene could render
the NSC line tumorigenic upon transplantation (Nakagawa
et al., 2010). However, the clonal v-MYC-immortalized hu-
man NSC line, HB1.F3.CD21, has shown chromosomal
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and functional stability over multiple passages and
good manufacturing practice (GMP) scale-up (Aboody
et al., 2013), and demonstrated clinical safety and non-
tumorigenicity in patients with recurrent glioblastoma
(NCT02015819). Another NSC line (CTX0E03) was estab-
lished in 2006 using the c-MYC gene commonly used in
generation of induced pluripotent stem cells (iPSCs)
(Pollock et al., 2006; Nakagawa and Yamanaka, 2010; Hicks
et al., 2013). In this case, a conditional technologywas used
to enable suppression of c-MYC via systemic tamoxifen
administration, if necessary, to ensure that c-MYC expres-
sion could be controlled upon transplantation (Pollock
et al., 2006).
These twoMYC-immortalizedNSC lines exhibit properties
that cause them to differ in their utility for treating diseases.
Specifically, HB1.F3.CD21 NSCs exhibit superior tumor
tropism butmore limited differentiation capacity compared
with CTX0E03 NSCs. These cells secrete bioactive factors
that are useful for promoting host neuronal plasticity or
vascular growth into damaged brain areas and have demon-
strated clinical efficacy in stroke patients (Stroemer et al.,
2009). The reasons for these differences are unknown, but
may arise from differences in the initial progenitor pools
chosen (gestational age), specifics of culture and transduc-
tion conditions, and chromosomal insertion points.
Thus while the potential of MYC immortalization for
the production of therapeutic NSC lines has been demon-
strated, realizing this potential will require generation
and validation of multiple lines optimized for particular
clinical applications. To facilitate this effort, we have devel-
oped a protocol for producing and characterizing new
MYC-immortalized NSC lines that can be propagated up
to at least passage 15 (p15). This protocol incorporates
two recent technological advances that should further
improve safety profiles relative to olderMYC-immortalized
NSC lines: (1) culture and freezing conditions that exclu-
sively use human-derived supplements, and, most impor-
tantly, (2) transduction with L-MYC to reduce the risk
of transformation (Nakagawa et al., 2008). L-MYC has
significantly lower transformation activity in cultured cells
than the otherMYCmembers (Oster et al., 2003), and only
a small number of human cancers have been associated
with the aberrant expression of L-MYC (Nakagawa et al.,
2010).
Here we describe the generation of the first L-MYC-
immortalized human NSC line derived from human fetal
brain, for brevity referred to as LM-NSC008. We find that
the LM-NSC008 line is chromosomally normal, and over-
expresses several stem cell-associated genes. LM-NSC008
cells proliferate faster than the parental cells, and can be
expanded under both suspension and adherent culture
conditions (an advantage for eventual clinical scale-up).
The LM-NSC008 stem cell line is non-tumorigenic when
injected to non-tumor-bearing mouse brain for up to
3 months (6- and 12-month studies are in progress).
Furthermore, these cells exhibit tumor-specific tropism,
and, on removal of growth factors, differentiate into neu-
ral, astrocytic, and oligodendroglial lineages, as do normal
non-immortalized NSCs. Once developed into a ‘‘clinical-
grade’’ stem cell line, LM-NSC008 may find widespread
use in stem cell-mediated therapies for CNS pathologies.
RESULTS
Generation and Characterization of L-MYC
Transduced NSC Clones
Cultures of dissociated NSCs were generated from human
fetal brain tissue of 10–14 weeks gestation. NSCs were
cultured under hypoxic conditions (4%O2) in a humidified
incubator (Binder). In growth factor-supplemented stem
cell medium, the primary hNSCs (NSC008) grew in sus-
pension and formed neurospheres (Figure 1A). At p2, we
transduced the primary NSC008 cells with retrovirus car-
rying L-MYC and puromycin resistance gene (MOI of
2.5). After 24–48 hr, transduced cells were grown in selec-
tion culture media containing puromycin (0.5 mg/mL),
which eliminated all untransduced cells within 2–3 days.
Cells were grown in puromycin for 28 days to select for
NSCs stably expressing the L-MYC gene. The LM-NSC008
cells grown under the same culture conditions as primary
NSC008 cells grew as a monolayer after two to three
passages in vitro (Figure 1B). This makes the LM-NSC008
cells more amenable to microscopic testing, cytology ex-
amination, and scale-up of cell production. Expression of
the L-MYC gene was confirmed by genomic PCR analysis
(Figure 1C). LM-NSC008 cells had normal karyotype at p2
and p10 in vitro (Figures 1D and 1E), and did not show
abnormal growth or tumorigenicity in vitro (Figure S1).
Soft agar colony formation assays in 1% agarose hydrogels
were performed to assess cellular anchorage-independent
growth of L-MYC (LM-NSC008)-transduced and v-MYC-
transduced (HB1.F3.CD) hNSC cells in vitro compared
with MCF7 breast cancer and 5,637 bladder cancer lines
(Figure S1). LM-NSC008 and HB1.F3.CD cells, in contrast
to the cancer cell lines (Figure S1A), did not form colonies
in soft agar, but rather remained viable as single cells (Fig-
ure S1B). These observations are quantified in Figure S1C.
In Vitro Growth Kinetics, Tumor-Specific Migration,
and Multilineage Differentiation of LM-NSC008 Cells
To determine whether the characteristics of these newly
derived NSCs changed after expansion and passage
in vitro, we compared primary NSC008 and LM-NSC008
grown through p6 with regard to viability, growth kinetics,
and NSC marker expression (Figure 2). Both transduced
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and untransduced cells showed >90% viability grown in
neurobasal medium under hypoxic conditions (4% O2).
The growth kinetics of primary NSC008 and LM-NSC008
cells differed significantly when tested in culture over
10 days (using p6 NSC008 and LM-NSC008), showing sig-
nificant differences in proliferation rate of NSC008 and
LM-NSC008 cells (p = 0.005 on day 5 and p = 0.002 on
days 7 and 10 as determined by multiple t test analysis
with Holm-Sidak adjustment for multiple comparisons)
(Figure 2A). The untransduced NSC008 did not proliferate
(initial cell number at plating on day 1 = 23 104/well, final
cell number on day 10 = 1.8 3 104) (Figure 2A, blue line),
whereas the LM-NSC008 cells showed robust proliferation
(initial cell number at plating on day 1 = 2 3 104, final cell
number on day 10 = 6.6 3 105; cell population doubling
time 30 hr for growth between days 5 and 10, after an
initial lag time from days 0–5, Figure 2A, red line). The
untransduced NSC008 stopped dividing approximately at
p6 to p10, while the LM-NSC008 cells continued to display
robust growth even at p15 (the highest passage number we
tested).
We used flow cytometry analysis and immunocytochem-
istry to detect stem cell and neural differentiation markers
expressed by LM-NSC008 cells (Figure 2B). Flow cytometry
revealed that virtually all undifferentiated primary NSCs
and LM-NSC008 cells expressed the neural stem cell
markers SOX2 and NESTIN, fewer cells expressed OCT4,
and virtually no cells were Olig-1, -2, or -3 positive, consis-
tent with a neural stem cell profile (Figure 2B). LM-NSC008
and primary NSC008 differed in expression of the stem
cell marker CD133, perhaps reflecting arrested develop-
ment related to L-MYC expression in proliferation media
(supplemented with fibroblast growth factor [FGF] and
epidermal growth factor [EGF]), LM-NSC008 cells divided
approximately every 36 hr, whereas they stopped dividing
under pro-differentiation conditions as previously reported
(Nunes et al., 2003) (Figure S2G).
To explore the therapeutic potential of LM-NSC008 cells,
we characterized their migration to tumor-conditioned
media in vitro. In Boyden chamber cell migration assays,
untransduced primary NSC008 at p6 exhibited little migra-
tion toward tumor cell-conditioned media compared with
LM-NSC008 cells at the same passage (Figure 2C). These
data suggest that after several passages in vitro, the un-
transduced parental NSC008 lack the abilities to proliferate
and migrate toward tumor-conditioned media, whereas
the LM-NSC008 cells possess proliferative and migratory
properties through at least p15 (Figure 2C). To demonstrate
the potential utility of LM-NSC008 cells in cancer-tar-
geted therapies, we adenovirally transduced LM-NSC008
cells to express a modified human CARBOXYLESTERASE
(CE; hCE1m6), which converts irinotecan (CPT-11) to
Figure 1. Visualization of Primary NSCs in Culture
(A) Primary NSCs (NSC008) were isolated from the brain of a 10-week-old fetus and cultured in flasks (passage 5). Primary NSCs grew as
neurospheres in suspension. Scale bar, 100 mm.
(B) Primary NSCs were transduced with a retroviral virus expressing the L-MYC gene. NSC.Lmyc cells (LM-NSC008) were cultured under the
same conditions as untransduced primary NSCs. LM-NSC008 cells preferentially grew as a monolayer. Scale bar, 100 mm.
(C) PCR analysis of genomic DNA derived from LM-NSC008 cells. The experiment was repeated three times.
(D and E) Karyotype analysis of the LM-NSC008 cell line at passage 2 (D) and passage 10 (E).
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SN-38, a potent topoisomerase I inhibitor (Wierdl et al.,
2008; Metz et al., 2013).We performed in vitro cytotoxicity
assays using human U251 glioma cells and various con-
centrations of irinotecan alone or in combination with
CE derived from LM-NSC008 cells adenovirally transduced
to express hCE1m6. We observed enhanced irinotecan
toxicity (500-fold) in the presence of hCE1m6 in the cul-
ture media when compared with CPT-11 alone. CE
(hCE1m6) activity was measured at 995 nmol/min/mL in
the conditionedmedia derived fromLM-NSC008 cells prior
to the cytotoxicity experiment (Figure 2D). This suggests
a potential use of LM-NSC008 cells for enzyme/prodrug
therapy to treat glioma and other tumors.
To probe the differentiation potential of LM-NSC008
cells in vitro (Figures 2E–2H), we immunostained differen-
tiated LM-NSC008 (grown for 10 days in differentiation
media) for class III b-tubulin, SOX9, glial fibrillary acidic
protein (GFAP), and O4. The immunoreactivity observed
indicated that LM-NSC008 cells were able to differen-
tiate into neurons (class III b-tubulin), astrocytes (SOX9,
GFAP), and oligodendrocytes (O4) (Figures 2E–2H). We
also compared differentiation of LM-NSC008with untrans-
duced primary NSC008 at p5 (Figure S3). Differentiated
LM-NSC008 cells and untransduced NSC008 cells showed
similar immunoreactivity for neuronal and glial markers
class III b-TUBULIN, SOX9, and GFAP (Figure S3).
Tumor-Directed Migration of hNSCs In Vivo
Anorthotopic gliomaxenograftmodelwas generated by in-
jecting U251.EGFP.ffluc human glioma cells (1 3 105/2 mL
Figure 2. Growth Kinetics and Migration of Primary NSC008 and LM-NSC008 Cells in Culture
(A) Proliferation of primary NSC008 and LM-NSC008 cells (passage 6) grown for 10 days in culture media (serum-free media containing FGF
and EGF). Mean values ± SD of two independent experiments in triplicate measurements are shown.
(B) Flow cytometry analysis of NSC008 and LM-NSC008 expressing stem cell markers. Mean values ± SD of four independent experiments in
triplicates are shown.
(C) Tropism of NSC008 and LM-NSC008 cells to conditioned media from U87 human glioma cells as assessed by Boyden chamber migration
assay. Mean values ± SD of three independent experiments in triplicate measurements are shown.
(D) Dose response of U251 human glioma cells to CPT-11 and to CPT-11 in the presence of hCE1m6 expressed by LM-NSC008 cells. Mean
values ± SD of two independent experiments in quadruplicates are shown. RLU, relative light unit.
(E–H) Immunocytochemical staining of LM-NSC008 cells grown for 10 days in differentiation media. Cells were stained for neuronal class
III b-TUBULIN (E), the astrocyte markers SOX9 (F) and GFAP (G) (inset Stem123), and oligodendrocyte marker O4 (H). Scale bars, 100 mm.
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PBS) into the right frontal hemisphere of adult NSG mice.
Seven days later, iron-labeled LM-NSC008 cells (2 3 105/
3 mL PBS) were injected intracranially and contralateral to
the tumor injection site (left frontal lobe, n = 6 tumor-
bearingmice, n = 2 control non-tumor-bearingmice). Con-
trol mice received sham injections of PBS into the right
frontal lobe instead of tumor. Mice were euthanized
4 days after receiving LM-NSC008 injections, and their
brains were harvested, fixed, sectioned, and stained for his-
tological examination. H&E and Prussian blue staining
were used to visualize tumors and LM-NSC008 cells, respec-
tively. Tumor sites were confirmed by immunostaining for
EGFP (Figure 3A, with tumor area enlarged in Figure 3D),
which revealed the presence of compact tumor nodules
located in the deep cortex and caudate-putamen, ranging
in diameter between 0.6 and 1 mm. Using Prussian blue
staining, we could often identify the injection site of iron-
labeled NSCs as a distinct, compact cellular focus located
contralateral to the tumor site. Iron-labeled LM-NSC008
cells were found at the tumor site by 4 days post injection
(Figure 3B, with tumor area enlarged in Figure 3E) having
migrated from the contralateral hemisphere. LM-NSC008
cells were mostly found in peripheral areas of the tumor
(Figure 3E), dispersed within tumor nodules (Figure 3F)
Figure 3. Tumor-Specific Migration of LM-NSC008 Cells from Contralateral Hemisphere In Vivo
(A, B, D, E) U251 human glioma xenografts were established in adult NSG mice. Consecutive horizontal brain sections from a tumor-
bearing mouse that received an intracranial (contralateral to the tumor) injection of LM-NSC008 cells (2 3 105) labeled with feraheme.
(A) Immunohistochemical staining of adjacent brain sections with EGFP antibodies to visualize tumor xenografts (scale bar, 1000 mm).
(D) Enlargement of tumor area shown as inset in (A) (scale bar, 100 mm). (B) Prussian blue staining of axial brain sections, feraheme-
labeled NSCs (blue) (scale bar, 1000 mm). (E) Higher-magnification of tumor site shown as inset in (B) with blue LM-NSC008 cells (scale
bar, 100 mm).
(C and F) Three-dimensional reconstruction of tumors (green) and LM-NSC008 cells (red) (n = 6). (F) 3D enlargement of tumor area shown
as inset in (C).
(G) A summary of 3D reconstructions of tumors and LM-NSC008 cells at the tumor site.
Scale bars 1,000 mm (A–C) and 100 mm (D–F). Asterisk indicates a mouse number.
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and in proximity to infiltrating tumor cells. Three-dimen-
sional (3D) reconstructionwas used to quantify thenumber
of NSCs at the tumor site and their spatial distribution
within the tumor (Figures 3C and 3F show a z-axis pro-
jection of 8–10 slices, 200 mm apart). Quantification of
LM-NSC008 cell numbers at the tumor site is summarized
in Figure 3G. We estimated that the average number of
LM-NSC008 cells within the tumor that migrated from
the opposite hemisphere was 310 ± 233. Immunostaining
for L-MYC confirmed its presence at the LM-NSC008 injec-
tion site and the tumor site in the contralateral hemisphere
(Figure S4A, enlarged in Figures S4B and S4C). Human kid-
ney tissue was used as a positive control for L-MYC staining
(Figure S4D). Negative control was obtained from omitted
primary antibody staining in the LM-NSC008 injection
site (Figure S4E) and tumor site (Figure S4F).
Migration of LM-NSC008 Cells to Sites of Traumatic
Brain Injury
To show the potential of LM-NSC008 cells to target injured
brain, we performed in vivo biodistribution experiments
using a controlled cortical impact (CCI) traumatic brain
injury (TBI) model. TBI was generated in adult C57BL/6
mice using an impactor device as described previously
(Brody et al., 2007). Sham-operated mice (without TBI)
were used as controls. The LM-NSC008 and HB1.F3.CD
NSCs (Kim et al., 2008) were administered intranasally on
days 9 and 11 following generation of moderate TBI or a
sham operation (n = 5 per group), as described previously
(Gutova et al., 2015). Mice received intranasal drops
of hNSCs (5 3 105 cells in 12 mL of PBS), equally divided
and administered into both nostrils. LM-NSC008 and
HB1.F3.CDNSCswere pre-labeledwithMolday ION rhoda-
mine B as described previously (Addicott et al., 2011). Brain
tissue was harvested 2–7 days after the last NSC administra-
tion, and iron-labeled hNSCs were visualized by Prussian
blue staining. 3D reconstruction was performed using
Prussian blue-stained sections. LM-NSC008 cells showed
robust migration to TBI injury sites (Figures 4A and 4B),
while sham-operated control mice had fewer LM-NSC008
stem cells at the surgery sites (Figures 4D and 4E). Numbers
of LM-NSC008 and HB1.F3.CD hNSCs were quantified
at TBI sites from z-axis projections of Prussian blue-stained
brain sections (Figures 4C and 4F), and total numbers of
hNSCs were calculated for each mouse. A summary is
presented in Figure 4G, comparing the results of: (1)
LM-NSC008 cell migration to TBI and sham injury sites,
****p = 0.00001; and (2) HB1.F3.CD migration to TBI and
sham sites, *p = 0.01. Comparison of TBI-directed migra-
tion of both hNSCs (LM-NSC008 and HB1.F3.CD) showed
significant difference among TBI-specific migration of
these lines, **p = 0.003. These data suggest that LM-
NSC008 administered intranasally can reach sites of CNS
injury in higher numbers than HB1.F3.CDs and have
the potential to be used for brain tissue repair and/or
regeneration.
LM-NSC008 Cell Fate in Normal Brain
To characterize the behavior of LM-NSC008 cells in normal
brain (no tumor or TBI), we injected 53 105 cells in 4 mL of
PBS into the right frontal lobe ofNSGmice (n = 6) (Figure 5).
Mice were placed into three groups that were euthanized
at 1, 4, or 12 weeks after LM-NSC008 injections. Brain sec-
tions were examined for the presence of viable LM-NSC008
cells, for the presence of markers indicating their fates
(proliferation, differentiation, or apoptosis). H&E staining
of paraffin-embedded sections showed foci of architectural
distortion associatedwith the presence of LM-NSC008 cells
at the injection site (not shown). Immunohistochemical
staining for human NESTIN confirmed the presence of
LM-NSC008 cells at the injection sites and minimal migra-
tion away from the site (Figures 5G–5I). TUNEL staining
indicated apoptosis of LM-NSC008 cells in normal brain
at 1, 4, and 12 weeks (Figures 5A–5C). Ki-67 staining (hu-
man-specific) indicated in vivo division of LM-NSC008
cells at 1, 4, and 12 weeks without formation of masses
caused by uncontrolled LM-NSC008 proliferation (Fig-
ures 5D–5F). We did not observe neurological symptoms
in mice that might be related to the injection of LM-
NSC008 cells.
To further demonstrate the lack of tumorigenicity, we
determined from IHC-stained brain sections the numbers
of Ki-67-positive cells per mouse brain and their locations.
Human NESTIN-positive cells (pseudocolored green) are
highlighted and merged with Ki-67-positive cells (red) in
Figures 5J–5L. The number of Ki-67-positive cells for each
mouse was compared with the total number of injected
cells (5 3 105/mouse), and their percentiles are presented
in Figure 5M. Quantification of human NESTIN expression
intensity is presented in Figure S5 and demonstrated a
time-dependent decrease in NESTIN expression at the
LM-NSC008 injection site.
Gene-Expression Profiling and Genome-wide Analysis
of Primary NSC008 and LM-NSC008 Cells
We performed RNA-sequencing (RNA-seq) analysis to
determine the transcriptional changes that occurred in
the newly derived NSCs in vitro with and without expres-
sion of L-MYC. To examine early and late passages, we iso-
lated RNA from primary untransduced NSC008 at p2 and
p9 (hNSC p2 and hNSC p9, respectively) and from
LM-NSC008 cells at p2 and p12 (LM-NSC008 p2 and LM-
NSC008 p12, respectively). We also differentiated the
LM-NSC008 cells in vitro, using a published protocol
(Nunes et al., 2003), and isolated RNA for analysis (LM-
NSC008 p12.Diff). We then performed RNA-seq expression
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profiling on the samples. To probe for differential gene
expression, we selected genes that showed either increased
or decreased expression based on results using EdgeR (Fig-
ure 6A), a Bioconductor package for differential expression
(DE) analyses of RNA-seq reads (Meng et al., 2014). We per-
formed three group comparisons using DE gene-selection
criteria: (1) absolute fold change (FC)R 3 (for comparisons
of hNSC p2 versus p9 and LM-NSC008 p2 versus p12); and
(2) absolute FCR 3 and p% 0.05 (for comparison of all pre-
vious samples with the LM-NSC008 p12 differentiated
Figure 4. Distribution of LM-NSC008 Cells to TBI Sites
(A) Prussian blue staining of brain section with TBI, demonstrating iron-labeled LM-NSC008 cells (blue) distributed throughout injury site.
Scale bar, 500 mm.
(B) Magnified area of TBI described in (A). Scale bar, 100 mm.
(C) 3D reconstruction of LM-NSC008 cells distributed in the vicinity of TBI site. Scale bar, 150 mm.
(D) Prussian blue staining of sham-injured brain section demonstrating rare (10–20) LM-NSC008 cells occasionally visualized around sham
surgery sites. Scale bar, 500 mm.
(E) Magnified area of injury site described in (D) Scale bar, 100 mm.
(F) 3D reconstruction of LM-NSC008 cell distribution in sham-injured brain. Scale bar, 150 mm.
(G) Quantification of average numbers of HB1.F3.CD and LM-NSC008 cells at TBI and sham injury sites (n = 5).
The arrows in (B, C, E, F) indicate LM-NSC008 cells in the vicinity of TBI or sham injury site. Statistical analysis of the treated and control
groups was performed using one-way ANOVA. Tukey’s adjusted p values are reported for pairwise comparisons of migration of hNSCs to TBI
and sham injury sites.
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Figure 5. LM-NSC008 Cell Fate in Non-Tumor-Bearing Brain
NSG mice were injected intracerebrally with LM-NSC008 cells (5 3 105, right frontal lobe) and euthanized 1 week (A, D, G), 4 weeks
(B, E, H), and 12 weeks (C, F, I) (n = 6) after injection.
(A–C) Immunohistochemical (IHC) detection of apoptotic NSCs by using TUNEL staining.
(D–F) IHC detection of the human-specific cell proliferation marker Ki-67.
(G–I) IHC of mouse brain tissue using human-specific NESTIN antibodies.
(J–L) z-Axis projection of all Ki-67- and hNESTIN-stained sections. NESTIN staining pseudocolored green and Ki-67 stained red.
(M) Quantification of the percentile of Ki-67-positive cells compared with the total injected dose of LM-NSC008 cells.
Scale bars, 100 mm.
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sample) (Figure 6A). Hierarchical clustering analysis was
performed using Cluster 3.0 and the average linkage clus-
tering method (de Hoon et al., 2004). The results were
visualized in Treeview and a heatmap was generated
(Saldanha, 2004) (Figure 6B). All up- and downregulated
genes were further analyzed using DAVID functional anno-
tation analysis to compare the same groups (LM-NSC008
p2 versus LM-NSC008 p12) (Table 1). Further analysis
compared hNSC008 p2 with hNSC008 p9 (Table S1) and
LM-NSC008 at p2 and p12 were also compared with the
LM-NSC008 differentiated sample (Table S2).
Comparison of gene expression in untransduced
NSC008 at p2 versus p9 revealed upregulation of genes
involved in pathways regulating neurogenesis, transmis-
sion of nerve impulses, synaptic transmission, nervous
system development, and cell-cell signaling (Tables S1
and S5). Genes involved in immune response and cell-
adhesion pathways were downregulated (Table S1). Upre-
gulated genes in the LM-NSC008 cells included those
involved in pathways responsible for regulating the devel-
opment of the neural system, while downregulated genes
were involved in cell adhesion and regulation of cell migra-
tion (Table 1). When NSC008 and LM-NSC008 cells were
compared with the differentiated LM-NSC008 cells, we
observed upregulation of regulators of cell growth and
wound healing, whilemetabolic pathways were downregu-
lated, indicating slower proliferation rates and differentia-
tion of LM-NSC008 cells cultured under pro-differentiation
conditions (Tables S2 and S5).
Analyses of somatic mutations and copy-number varia-
tions with whole-exome sequencing were also performed
to check for potential mutation events or changes in
the karyotype as a result of L-MYC expression. Only eight
somatic mutations were identified when comparing
LM-NSC008 p12with LM-NSC008 p2. Of these eightmuta-
tions, six were located in introns and two were synony-
mous, so none were considered functional and most likely
represent germline mutations. We also did not observe
any large copy-number variations, with only two regions
covering two coding exons of gene CDKL1 and MYLK
showing possible loss of one allele in the p12 sample (Table
S4). Overall, we concluded that there were no significant
differences in the genomic sequences between the p12
and p2 samples, indicating that L-MYC gene expression
did not contribute to increased genomic instability in
LM-NSC008 cells.
DISCUSSION
We chose L-MYC to generate immortalized hNSC lines for
therapeutic purposes based on its low tumorigenicity, as
reported by Nakagawa et al. (2010). In this study we
have shown that expression of the L-MYC gene in human
fetal brain-derived NSCs can promote self-renewal and
multipotency in these cells. Untransduced NSCs from
the same primary pool proliferate for only a limited num-
ber of passages in vitro before undergoing apoptosis.
Our findings demonstrate that stable expression of the
L-MYC gene in NSC008 cells promotes their survival and
proliferation while preserving their migration and differ-
entiation properties in vitro and in vivo. In this way,
the LM-NSC008 cells will provide for GMP grade produc-
tion as well as modification for therapeutic purposes.
RNA- and DNA-sequencing analyses suggest that the
L-MYC gene regulates distinct sets of target genes (Naka-
gawa et al., 2008, 2010). Most likely the L-MYC gene
acts to suppress expression of genes involved in differen-
tiation, as was demonstrated previously (Nakagawa et al.,
2010). At the same time, analysis of specific somatic
Figure 6. Summary of Up- and Downregu-
lated Genes within Samples Analyzed
(A) Untransduced NSC008 at passage 2
were compared with NSC008 at passage 9,
L-MYC transduced cells (LM-NSC008) were
compared at passages 2 versus 12, and
NSC008 and LM-NSC008 cells were compared
with differentiated LM-NSC008 cells.
(B) Heatmap showing upregulated (red) and
downregulated (green) genes.
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mutations demonstrated that L-MYC expression in LM-
NSC008 cells did not increase their genetic instability.
The LM-NSC008 cells also recapitulated important phe-
notypes of NSCs: after differentiation, the LM-NSC008
cells expressed neuronal class III b-TUBULIN, astroglial
markers SOX9 and GFAP, and oligodendrocyte marker
O4, which coincided with neuronal, astrocytic, and oligo-
dendroglial morphologies, respectively (Figures 2E–2H)
(Wegner and Stolt, 2005; Sofroniew and Vinters, 2010).
These are key characteristics that stem cells must display
if they are to be used in cell-replacement therapies for
neurodegenerative diseases or brain injury (Lemmens and
Steinberg, 2013; Tang et al., 2013).
The MYC genes orchestrate diverse cellular functions in
the normal cells, including self-renewal and proliferation,
morphological maturation, apoptosis, energy utilization,
and multipotent differentiation (Conacci-Sorrell et al.,
2014). Nakagawa et al. (2010) previously showed that
L-MYC has the lowest transformational activity of the
MYC isoforms in iPSCs, as well as a robust ability to repro-
gram cells for generation of iPSCs. Our gene-expression
profiling data are in accord with the reported wide-ranging
effects of L-MYC gene expression in hNSCs. The large
number of upregulated genes (1,213) and downregulated
genes (1,045) in LM-NSC008 p2 versus LM-NSC008 p12
(Figure 6) may reflect the complex protein interactome in
which L-MYC participates directly or indirectly via its
DNA-binding and transactivation domains (Tu et al.,
2015). The robust changes in the gene-expression profile
also suggest that the introduction of the L-MYC gene into
hNSCsmay lead to epigenetic plasticity that could underlie
the large-scale changes in gene expression (Arrowsmith
et al., 2012; Watanabe et al., 2013).
Research on the ‘‘druggable epigenome’’ and the use
of small-molecule drugs to break the epigenetic barrier
by modulating the activity of enzymes acting on the
epigenome (e.g., DNA methylases/demethylases, his-
tone methyltransferases/demethylases, acetyltransferases/
deacetylases, and RNAi) has led to advances in basic as well
as translational science, including clinical development
(Arrowsmith et al., 2012).We surmise that in future research
epigenome-modulating drugs may be applicable for optimi-
zation of the tumor-targeting and therapeutic properties
of therapeutic NSCs, including the LM-NSC008 cells. Such
studies could use LM-NSC008 cells deposited in a master
cell bank, from which various subclones obtained by epige-
netic reprogramming could be generated. In addition, anal-
ysis of the immunological parameters of the LM-NSC008
cellswill be a crucial componentof futurepre-clinical studies
using this cell line. Such immunological parameters could
include the levels of major histocompatibility complex
class I and class II gene expression (that could determine
the immunological interactions between the transplanted
NSCs and the host immune system), as well as expression
profiling of various cytokine receptor genes in the LM-
NSC008 cells, which could underlie the signaling pathways
responsible for tumor tropism and targeting of the nervous
system affected by various pathological conditions.
In summary, we have generated a stable, expandable
human NSC line (LM-NSC008) by overexpression of the
L-MYC gene. We have characterized the LM-NSC008 cell
line in vitro and in vivo. Our findings demonstrate the
potential therapeutic utility of LM-NSC008 cells for thera-
peutic drug delivery to CNS tumors, restorative therapies
for TBI, and possibly other diseases of the CNS. Further
pre-clinical studies in CNS disease models are warranted
for translational development and eventual clinical use of
L-MYC-transduced NSC lines.
EXPERIMENTAL PROCEDURES
Generation and Characterization of Primary NSC
Cultures
Fetal brain from elective abortions was obtained as discarded tissue
from Advanced Bioscience Resources under a City of Hope Institu-
tional Review Board approved protocol (City of Hope IRB #10079).
All procedures that involved stem cell isolation and propagation
were performed under approved protocols (City of Hope SCRO
#11002, and IBC #11016). Human brain tissue (from fetuses of
10–14 weeks of gestation) was dissociated using 0.1% collagenase
and hyaluronidase solution (3,000 U/mL collagenase, 1,000 U/mL
hyaluronidase in Hank’s balanced salt solution), and isolated NSCs
were cultured in serum-free NSC medium (RHB-A medium; Stem
Table 1. DAVID Functional Annotation Analysis of LM-NSC008
at Passage 2 versus LM-NSC008 at Passage 12
Term
Fold
Enrichment Count p Value
Top 5 Enriched Pathways Upregulated
Neuron differentiation 3.154299 72 3.73 3 1018
Transmission of nerve impulse 3.125009 57 3.55 3 1014
Synaptic transmission 3.219573 50 5.28 3 1013
Cell-cell signaling 2.430563 76 8.98 3 1013
Cell adhesion 2.247814 82 6.21 3 1012
Top 5 Enriched Pathways Downregulated
Cell adhesion 2.77224 104 8.81 3 1022
Biological adhesion 2.768286 104 9.83 3 1022
Regulation of cell motion 4.447297 46 1.65 3 1017
Cell motion 2.906924 74 1.13 3 1016
Actin cytoskeleton organization 3.963039 48 4.85 3 1016
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Cell Science) supplemented with 10 ng/mL basic FGF (bFGF),
10 ng/mL EGF, 2 mM L-glutamine (Invitrogen), Gem21 NeuroPlex
Serum-FreeSupplement (GeminiBio-Products, #400-160), andpeni-
cillin-streptomycin (Mediatech, 30-002-CI). Growth factors (bFGF
and EGF) were added every other day and media were completely
changed every 7 days. Cells were passaged by gentle trituration of
neurospheres.
RNA and DNA were isolated from LM-NSC008 p2 and p12,
NSC008 p2 and p9, and differentiated LM-NSC008 cells to char-
acterize gene expression. LM-NSC008 cells were differentiated
in vitro by culturing in DMEM medium supplemented with 1%
fetal bovine serum for 10 days as previously described (Nunes
et al., 2003). Samples for karyotype determination were prepared
for G-banding karyotyping analysis using standard cytogenetic
methods at City of Hope Cytogenetics Core Facility.
Generation of NSC Lines that Stably Express the L-
MYC Transgene
The L-MYC expression vector (pMXs-hu-L-Myc) was obtained from
Addgene (Okita et al., 2013). The L-MYC gene from pMXs-hu-
L-Myc was recloned into a retroviral expression vector (pCMV-LL-
PGK-puro) containing the puromycin selection marker. Retrovirus
carrying the L-MYC genewas used for transduction of human fetal-
derived NSCs at MOI 2.5.
Boyden Chamber Cell Migration Assay
In vitro chemotaxis assays were conducted using 24-well cell-cul-
ture plates with polycarbonate inserts (8-mm pore size; Millipore)
as described previously (Gutova et al., 2010). An independent t
test was performed to determine the statistically significant differ-
ence between NSC008 and LM-NSC-008 migration to U87 condi-
tioned media (p = 0.0003).
Cytotoxicity Assays
Detailed methodology is presented in Supplemental Experimental
Procedures.
Colony Formation Assay
Detailed methodology is presented in Supplemental Experimental
Procedures.
Iron Labeling of NSCs
Human NSCs (HB1.F3.CD and LM-NSC008) were labeled with
Molday ION rhodamine B prior to intranasal administration.
LM-NSC008 cells and HB1.F3.CDs were visualized within brain
tissue by Prussian blue staining using an Accustain Iron Stain Kit
(Sigma-Aldrich).
Immunohistochemistry and Immunocytochemistry
Detailed methodology is presented in Supplemental Experimental
Procedures.
Flow Cytometry Analysis of Primary NSC008 and
LM-NSC008 Cells
Detailed methodology is presented in Supplemental Experimental
Procedures.
Serial Section Reconstruction and Measurement
Reconstruction and measurement was performed using Recon-
struct (version 1.1.0.1) (Fiala, 2005) software as described previ-
ously (Gutova et al., 2013). In brief, 7–11 serial brain sections
(10 mm each) separated by 200 mm were imported into the Recon-
struct program and aligned manually. NSC quantification was per-
formed using bright-field Prussian blue images, and autotracing of
the tumor was done on adjacent EGFP-stained images. From the
number of NSCs on each section analyzed, the total number of
cells per brain was calculated using spacing between stained sec-
tions and approximation of NSC numbers on unstained sections.
Animal Studies of LM-NSC008 Cell Distributions
All animal studies were performed under approved City of Hope
Institutional Animal Care and Use Committee protocols (IACUC
12025). Animal studies used NOD scid IL2Rgammanull (NSG) mice,
8–12weeksold regardless of sex. Fordistribution studies, orthotopic
tumor xenografts were generated by injecting human U251.EGFP.
fflucgliomacells (13105 in2mLof serum-freeDMEM) intothe right
frontal lobe ofNSGmice (study day 1). LM-NSC008 cells (23 105 in
3 mL of PBS) were injected contralaterally to the tumor (n = 6 mice)
on day 7 of the study. Controlmice (n = 2) did not receive tumor in-
jection, but did receive sham injection of PBS (tomimic injection of
tumor cells) and NSCs on the opposite side of the brain. Mice were
evaluated for clinical signsbefore andafter tumororNSC injections.
Experimental animals were monitored daily for any debilitating
signs secondary to tumor growth, including: labored breathing,
weight loss (>20% body weight), scruffy coat, hunched posture,
hypo- or hyperthermia, impaired ambulatory movement, and
inability to remainupright.Tumorswere confirmedbyXenogen im-
aging prior toNSC administration. Allmicewere euthanized onday
4 after NSC administration. Brainswere removedwithout perfusion
and processed for histological examination using H&E and EGFP
immunostaining to detect tumors and tissuemorphology. Prussian
blue staining was done to identify Molday ION-labeled NSCs, as
described previously (Addicott et al., 2011).
TBI was generated in adult (C57BL/6)Cdh23ahlmice via impactor
device as described previously (Brody et al., 2007). In brief, mice
were subjected to a single moderate left lateral (CCI) injury
with craniotomy under isoflurane anesthesia. An electromagnetic
impact device was used for generation of moderate contusion TBI
using the following bregma coordinates: x axis, 1.2 mm left of
midline; y axis, 1.5 mm anterior to lambda and 2 mm deep. After
the probe was inserted into the brain (2 mm deep), the dwell
time was 100 ms. The hole was then covered with a plastic skull
cap and the skin was sutured. Sham TBI injury was performed on
a control group of mice, which included craniotomy but no
impactor stimulation, as described previously (Brody et al., 2007).
Intranasal Administration of NSCs
LM-NSC008 and HB1.F3.CD cells were administered intranasally
on days 9 and 11 after mild TBI. Mice received intranasal drops of
either LM-NSC008 or HB1.NSC.CD cells (5 3 105 cells per 12 mL/
mouse) into both nostrils divided equally (6 mL) with 2-min inter-
vals pre-labeled with Molday ION rhodamine B (Addicott et al.,
2011; Gutova et al., 2015). Mice were euthanized 2 weeks after
the last NSC administration. Brain tissue was harvested and fixed
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in 4% paraformaldehyde. Paraffin-embedded sections were pre-
pared and Prussian blue staining was performed to visualize iron-
labeledhNSCs.Prussianblue-stained sectionswereused toquantify
the number of hNSC cells in each brain for TBI and sham groups.
In Vivo Tumorigenicity Studies
For determination of the fate of NSCs in non-tumor-bearingmouse
brain, NSG mice were injected with 5 3 105 NSCs (n = 6) intracra-
nially and were euthanized at 1, 4, and 12 weeks after injection,
after which their brains were harvested. The brains were then
isolated, fixed, and stained (every tenth section) with H&E (Amer-
ican Master Tech Modified Mayer’s H&E), Ki-67 (Dako), TUNEL
(Chemicon), and human NESTIN (Millipore). Quantification of
percentile Ki-67-positive cells was performed using previously
stained sections relative to the dose on LM-NSC008 cells injected.
mRNA Deep Sequencing with Illumina Hiseq2500
Detailed methodology is presented in Supplemental Experimental
Procedures.
RNA-Seq Data Analysis
Detailed methodology is presented in Supplemental Experimental
Procedures. The records of RNA-seq data have been approved and
assigned the accession number GEO: GSE84166.
Whole-Exome Sequencing for Somatic Mutations and
Copy-Number Variation Analysis
Detailed methodology is presented in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
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